Dassanayake TL, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, et al. Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series study in Australia. CNS Drugs 2012;26(3):269–276. .[PubMed]
Dassanayake TL, Michie PT, Jones AL, Mallard T, Whyte IM, Carter GL. Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs. Traffic Inj Prev 2012;13(5):450–457. .[PubMed]
Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008;30(4):490-6. https://www.ncbi.nlm.nih.gov/pubmed/18641540
Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986;15(5):566–70. https://www.ncbi.nlm.nih.gov/pubmed/3963538
Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol 2016;56(10):1243–53. https://www.ncbi.nlm.nih.gov/pubmed/27145977
Phebra. NARCAN injection [product information]. Sydney, New South Wales: Phebra Pty Ltd; Amended Feb 2013 Accessed www.tga.gov.au
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9(1):63–88. https://www.ncbi.nlm.nih.gov/pubmed/29318006
